Roman Butler Fullerton & Co. Acquires New Stake in Exelixis, Inc. $EXEL

Roman Butler Fullerton & Co. acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 168,589 shares of the biotechnology company’s stock, valued at approximately $9,847,000. Exelixis makes up about 2.2% of Roman Butler Fullerton & Co.’s portfolio, making the stock its 7th biggest position. Roman Butler Fullerton & Co. owned approximately 0.07% of Exelixis at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in EXEL. BlackRock Inc. purchased a new position in shares of Exelixis in the 2nd quarter valued at approximately $1,581,991,000. Caisse de depot et placement du Quebec purchased a new stake in Exelixis in the second quarter worth $113,951,000. Bank of New York Mellon Corp purchased a new stake in Exelixis in the second quarter worth $107,803,000. Jupiter Topco LLC bought a new position in Exelixis in the second quarter worth $67,299,000. Finally, First Trust Advisors LP raised its holdings in Exelixis by 62.0% in the first quarter. First Trust Advisors LP now owns 2,534,992 shares of the biotechnology company’s stock worth $108,726,000 after purchasing an additional 970,144 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Ratings Changes

EXEL has been the topic of a number of recent research reports. Citigroup reaffirmed a “market outperform” rating on shares of Exelixis in a research report on Monday, October 19th. Wells Fargo & Company lifted their price target on shares of Exelixis from $40.00 to $49.00 and gave the company an “equal weight” rating in a research report on Monday, July 13th. William Blair reissued an “outperform” rating on shares of Exelixis in a research note on Friday, September 11th. HC Wainwright reissued a “buy” rating and set a $56.00 price objective on shares of Exelixis in a research note on Thursday, July 2nd. Finally, Weiss Ratings upgraded shares of Exelixis from a “buy (a-)” rating to a “buy (a)” rating in a report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $51.50.

Insider Transactions at Exelixis

In other news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the sale, the director owned 16,079 shares in the company, valued at $862,799.14. This represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.60% of the company’s stock.

Exelixis Price Performance

Exelixis stock opened at $65.35 on Wednesday. Exelixis, Inc. has a 12 month low of $36.00 and a 12 month high of $65.58. The business’s fifty day simple moving average is $58.57 and its two-hundred day simple moving average is $50.57.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.06. The company had revenue of $628.69 million for the quarter, compared to the consensus estimate of $636.40 million. Exelixis’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.75 earnings per share. Sell-side analysts predict that Exelixis, Inc. will post 3.19 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.